Benjamin Robert S, Debiec-Rychter Maria, Le Cesne Axel, Sleijfer Stefan, Demetri George D, Joensuu Heikki, Schöffski Patrick, Poveda Andrés
Department of Sarcoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Semin Oncol. 2009 Aug;36(4):302-11. doi: 10.1053/j.seminoncol.2009.06.003.
The finding of mutations of KIT in gastrointestinal stromal tumors (GISTs) and subsequent development of kinase-directed therapy in metastatic GIST serve as a touchstone for the translation of laboratory research into clinical therapeutics. A variety of novel developments have followed the discovery of clinical activity of kinase-directed therapy against GIST. Radiological assessment of GIST challenges the standard of care for assessing tumor responses, ie, Response Evaluation Criteria in Solid Tumors (RECIST). Furthermore, the determination of the relationship of specific KIT mutations and sensitivity and resistance to kinase-directed agents and the assessment of inhibitor levels and the quality of response to those agents have implications beyond the treatment of sarcomas. These discoveries and the next chapters in this developing story are discussed in this review.
胃肠道间质瘤（GISTs）中KIT突变的发现以及转移性GIST中激酶导向疗法的后续发展，成为了将实验室研究转化为临床治疗的试金石。激酶导向疗法对GIST具有临床活性这一发现之后，出现了一系列新进展。GIST的影像学评估对评估肿瘤反应的护理标准提出了挑战，即实体瘤疗效评价标准（RECIST）。此外，特定KIT突变与对激酶导向药物的敏感性和耐药性之间关系的确定，以及抑制剂水平的测定和对这些药物反应质量的评估，其意义不仅限于肉瘤的治疗。本综述将讨论这些发现以及这个不断发展的故事的后续章节。
